ZYME Key Statistics, Chart & Performance
The current stock price of ZYME is 25.1 USD. In the past month the price increased by 32.87%. In the past year, price increased by 76.14%.
ZYME Latest News, Press Relases and Analysis
ZYME Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.74 | 396.55B | ||
| AMGN | AMGEN INC | 15.47 | 182.20B | ||
| GILD | GILEAD SCIENCES INC | 15.13 | 153.73B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.95 | 109.90B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.49 | 77.98B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 911.63 | 61.42B | ||
| INSM | INSMED INC | N/A | 44.06B | ||
| NTRA | NATERA INC | N/A | 32.66B | ||
| BIIB | BIOGEN INC | 10.76 | 26.43B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.97 | 20.42B | ||
| INCY | INCYTE CORP | 15.8 | 19.91B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.20B |
Related stock screener links
About ZYME
Company Profile
Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. The company is headquartered in Middletown, Delaware and currently employs 273 full-time employees. The company went IPO on 2019-06-24. The firm is developing a diverse pipeline of multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases such as cancer, autoimmune and inflammatory diseases (AIID). The firm engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s Azymetric technology. The company has entered into separate agreements with BeiGene, Ltd. and Jazz Pharmaceuticals Ireland Limited, granting each exclusive rights to develop and commercialize zanidatamab in different territories. The company is advancing a pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. The firm has two clinical-stage product candidates: ZW171 and ZW191. Its preclinical product candidates include ZW251, ZW220, ZW209, and ZW1528.
Company Info
ZYMEWORKS INC
108 Patriot Drive, Suite A
Middletown DELAWARE V6H 3V9 US
CEO: Ali Tehrani
Employees: 273
Phone: 13022748744
ZYMEWORKS INC / ZYME FAQ
What does ZYMEWORKS INC do?
Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. The company is headquartered in Middletown, Delaware and currently employs 273 full-time employees. The company went IPO on 2019-06-24. The firm is developing a diverse pipeline of multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases such as cancer, autoimmune and inflammatory diseases (AIID). The firm engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s Azymetric technology. The company has entered into separate agreements with BeiGene, Ltd. and Jazz Pharmaceuticals Ireland Limited, granting each exclusive rights to develop and commercialize zanidatamab in different territories. The company is advancing a pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. The firm has two clinical-stage product candidates: ZW171 and ZW191. Its preclinical product candidates include ZW251, ZW220, ZW209, and ZW1528.
What is the current price of ZYME stock?
The current stock price of ZYME is 25.1 USD. The price decreased by -3.57% in the last trading session.
What is the dividend status of ZYMEWORKS INC?
ZYME does not pay a dividend.
What is the ChartMill rating of ZYMEWORKS INC stock?
ZYME has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
Can you provide the sector and industry classification for ZYMEWORKS INC?
ZYMEWORKS INC (ZYME) operates in the Health Care sector and the Biotechnology industry.
How is the valuation of ZYMEWORKS INC (ZYME) based on its PE ratio?
ZYMEWORKS INC (ZYME) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.84).
Would investing in ZYMEWORKS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ZYME.
ZYME Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to ZYME. When comparing the yearly performance of all stocks, ZYME is one of the better performing stocks in the market, outperforming 95.92% of all stocks.
ZYME Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to ZYME. While ZYME has a great health rating, there are worries on its profitability.
ZYME Financial Highlights
Over the last trailing twelve months ZYME reported a non-GAAP Earnings per Share(EPS) of -0.84. The EPS increased by 34.37% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -15.97% | ||
| ROE | -19.82% | ||
| Debt/Equity | 0 |
ZYME Forecast & Estimates
18 analysts have analysed ZYME and the average price target is 24.62 USD. This implies a price decrease of -1.92% is expected in the next year compared to the current price of 25.1.
For the next year, analysts expect an EPS growth of 36.42% and a revenue growth 66.87% for ZYME